Relief Therapeutics Holding AG (RLFTF)

[ratna1]

For simplicity's sake I will copy another poster on the EARS board


LINK Oracle Member Level Tuesday, 04/13/21 09:53:21 AM
Re: None 0
Post #
671
of 671
COVID News AM-301 helps to reduce growth in infectious titer in ongoing SARS-CoV-2 infection

In parallel with the outcomes from the allergy studies, Altamira Medica obtained first data from testing AM-301 after the start of infection of human nasal epithelium cells with SARS-CoV-2. In a previous study in the same type of assay, AM-301 had been shown to be highly effective in reducing the infectious viral titer when daily treatment was started right before inoculation of the cells, i.e. in a preventative fashion. In the new experiment, daily treatment with AM-301 started 24 or 30 hours post inoculation. Saline- and vehicle-treated and untreated cell cultures served as controls.

In control cultures, SARS-CoV-2 replicated efficiently over four days, resulting in a rapid increase in viral titer (as measured by the Median Tissue Culture Infectious Dose, TCID50, in Vero cells). Daily treatment with AM-301 resulted in a statistically significant deceleration of the viral titer growth compared to controls (p-value <0.01, linear mixed-effects model). At Day 4 of the experiment, viral titers were 73.7 to 94.5% lower compared to controls.

https://www.otcmarkets.com/stock/EARS/news/story?e&id=1862250